Tech Company Financing Transactions

REN Pharmaceuticals Funding Round

REN Pharmaceuticals, operating out of South San Francisco, scored $1.1 million from Amgen Ventures, Sanderling Ventures and Venrock.

Transaction Overview

Announced On
12/31/2006
Transaction Type
Venture Equity
Amount
$1,050,000
Round
Undisclosed
Investors

Amgen Ventures (Michael Narachi)

Sanderling Ventures (Paul Grayson)

Venrock (Bryan Roberts)

Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
270 E. Grand Ave.
South San Francisco, CA 94080
USA
Email Address
Overview
The company's mission is to develop and commercialize breakthrough therapeutics for renal diseases and associated cardio-renal diseases.
Profile
REN Pharmaceuticals LinkedIn Company Profile
Social Media
REN Pharmaceuticals Company Twitter Account
Company News
REN Pharmaceuticals News
Facebook
REN Pharmaceuticals on Facebook
YouTube
REN Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mike Narachi
  Mike Narachi LinkedIn Profile  Mike Narachi Twitter Account  Mike Narachi News  Mike Narachi on Facebook
VP - Bus. Development
Angie You
  Angie You LinkedIn Profile  Angie You Twitter Account  Angie You News  Angie You on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/31/2006: GameRiot venture capital transaction
Next: 12/31/2006: ScanScout venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to document all VC transactions involving tech companies. VC investment data records on this site are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary